13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274403
Total reported value
$1.1B
$1.1B
8 檔
6.6%
The Q1 2024 SEC filing reveals that ARCH Venture Management, LLC held a total portfolio value of $1.1B, covering 8 public equity positions.
In Q1 2024, ARCH Venture Management, LLC displayed an active expansion posture, initiating 2 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Verve Therapeutics Inc | Stock-Other | 33.23% | — | — | |
| 2 | ERAS | Erasca Inc | Stock-Other | 28.37% | -5.14% | — | |
| 3 | GOSS | Gossamer Bio Inc | Stock-Other | 11.84% | -0.27% | — | |
| 4 | DNLI | Denali Therapeutics Inc | Stock-Other | 9.75% | — | — | |
| 5 | QTTB | Q32 Bio Inc | Stock-Other | 6.80% | -0.30% | EXIT | |
| 6 | FENG | Phoenix New Media Limited | Stock-Other | 5.52% | — | — | |
| 7 | ✓ | Singular Genomics Systems In | Stock-Other | 2.43% | — | — | |
| 8 | UNBX | Unity Biotechnology Inc | Stock-Other | 2.05% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Verve Therapeutics Inc | +16.1% | — | Unchanged |
| 2 | ERAS | Erasca Inc | +14% | — | Unchanged |
| 3 | GOSS | Gossamer Bio Inc | +7.3% | — | Unchanged |
| 4 | QTTB | Q32 Bio Inc | +6.8% | NEW | New buy |
| 5 | FENG | Phoenix New Media Limited | +5.5% | NEW | New buy |
| 6 | DNLI | Denali Therapeutics Inc | +4.8% | — | Unchanged |
| 7 | ✓ | Singular Genomics Systems In | +1.4% | — | Unchanged |
| 8 | UNBX | Unity Biotechnology Inc | +0.9% | — | Unchanged |
| 9 | RVMD | Revolution Medicines Inc | -56.7% | EXIT | Sold out |
According to official SEC Form 13F filings, ARCH Venture Management, LLC reported a total U.S. public equity portfolio value of $1.1B across 8 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VERVE THERAPEUTICS INC, ERAS, GOSS) accounted for 6.6% of total reported equity market value during Q1 2024.
Top New Position Initiated
QTTB
市值: $5.5M
Top Position Liquidated / Trimmed
RVMD
前期市值: $92.7M
During Q1 2024, ARCH Venture Management, LLC's top holdings by market value included VERVE THERAPEUTICS INC (33.2%)、ERAS (28.4%)、GOSS (11.8%). The largest single position, VERVE THERAPEUTICS INC, represented 33.2% of total portfolio value.
In Q1 2024, ARCH Venture Management, LLC made 3 total portfolio adjustments, initiating 2 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.